



Evolution of Transdermal Drug Delivery Devices and Novel Microneedle Technologies: A Historical Perspective and Review

Naveen Joshi¹, Sina Azizi Macheuposhti² and Roger J. Narayan^{1,2}

The history of transdermal drug delivery is as old as humankind. Transdermal drug delivery has undergone three generations of development; the third generation has involved the use of medical devices and instruments. This review provides a historical perspective on the primary approaches employed in the three generations of transdermal drug delivery. In addition, we explore some of the recently developed transdermal techniques that are deemed promising in the field of drug delivery. We discuss how advances in these techniques have led to the development of devices for the delivery of a therapeutically effective amount of drug across human skin and highlight the limitations of the first- and second-generation drug delivery tools. As such, a review of the performance of these techniques and the toxicity of the devices used in transdermal drug delivery are considered. In the last section of the review, a discussion of the fabrication and operation of different types of microneedles is presented. The applications of microneedles in the sensing and delivery of various therapeutic agents are described in detail. Furthermore, an overview of the efficacy of microneedles as emerging tools for the controlled release of drugs is presented.

JID Innovations (2023);3:100225 doi:10.1016/j.xjidi.2023.100225

INTRODUCTION

Drug delivery through the skin is a growing focus of pharmaceutical research. The skin is the largest organ in humans, which provides a protective barrier against water loss, injury, and infection (Sabbagh and Kim, 2022). The surface area of

the skin in the adult is between 1.5 and 2.0 m². The epidermis, dermis, and hypodermis are the three main layers of the skin. The dermis is composed of sweat glands, nerve endings, hair follicles, and lymphatic vessels. It is approximately 3–5 mm thick. The epidermis is the outer layer of human skin that exhibits a thickness of 60–800 μm; the uppermost sublayer of the epidermis is known as the stratum corneum. The stratum corneum, with a thickness of 10–20 μm, serves as a barrier to water loss and the movement of external materials into the body (Chien, 1991). Figure 1 shows a cross-sectional schematic of the human skin.

Transdermal drug delivery is being investigated as an alternative to conventional oral drug delivery and intravenous injection methods. It has been common practice for thousands of years to apply substances or plants to the skin; for instance, a wide range of formulations have been prepared for localized treatment. For example, the use of salves, plants, minerals, or animal extract patches was popular in ancient Babylonian and Egyptian medicine around 3000 BC (Geller, 2010; Magner and Kim, 2017; Pastore et al., 2015). Topical therapies were placed on the skin by bandaging and rubbing, as described on Sumerian clay tablets (Kramer, 1963). An ochre-rich mixture was liquefied for use as skin protection and decoration in Blombos Cave in South Africa approximately 100,000 years ago (Henshilwood et al., 2011; Pastore et al., 2015). Natural oils (e.g., olive, castor, and sesame oil), animal fats, perfumes (e.g., peppermint, bitter almond, and rosemary), unguents, creams, pomades, rouges, and powders were used by ancient people for cosmetic or dermatological purposes (Forbes, 1964). Several hundred drugs were mentioned in the *Papyrus Eber*, which dates to 1550 BC. It has helpful information on treating wounds, blisters, and exudation (Packard, 1927). Transdermal drug delivery approaches were described by well-known individuals such as Galen (AD 129–199) and Ibn Sina (AD 980–1037). Galen, the father of pharmacy, made a cold cream with similar use as current products (Gaskell, 1967). Ibn Sina showed that each topical drug has soft and hard forms. The soft form can penetrate the skin layers; the hard form was applied on top of the skin. Moreover, he suggested that the penetrated portion would reach systematic circulation. As an example, he mixed sulfur and tar and made a plaster-like formulation for treating sciatica (Moghimi et al., 2011; Pastore et al., 2015). Several new transdermal products have been developed for delivering a greater number of pharmaceutical ingredients. A 3-day scopolamine patch for treating motion sickness was the first systemic delivery in 1979 in the United States. Nicotine patches were subsequently approved for use. Nowadays, the number of medicinal patches for transdermal drug delivery is

¹Department of Materials Science and Engineering, College of Engineering, North Carolina State University, Raleigh, North Carolina, USA; and ²Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina, USA

Correspondence: Roger J. Narayan, Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695-7115, USA. E-mail: roger_narayan@ncsu.edu


Abbreviations: 3D, three-dimensional; DOD, drop-on-demand; TENG, triboelectric nanogenerator

Received 31 December 2022; revised 12 August 2023; accepted 16 August 2023; corrected proof published online XXX

Cite this article as: *JID Innovations* 2023;3:100225

Figure 1. Cross-section of human skin.

Histological layers of the skin, including the epidermis, dermis, and hypodermis are shown in the figure. This image was reprinted with permission from Sabbagh and Kim (2022).



increasing. A new patch was approved every 2.2 years between 1979 and 2002, and this value increased to one new patch every 7.5 months from 2003 to 2007; this number continues to increase (Chu et al., 2016; Guy and Hadgraft, 2003; Prausnitz and Langer, 2008; Wester and Maibach, 1993; Williams, 2003).

Each drug administration route has its own advantages and disadvantages. For example, the oral route is pain free and convenient; however, many types of drugs are metabolized in the liver before entering the systemic circulation. In contrast, transdermal delivery is often associated with pain-free delivery and a low probability of complications. In addition, transdermal drug delivery provides the controlled release of drugs over an extended period of time (A Machekposhti et al., 2017). One of the most important challenges of the transdermal drug delivery method is the limited number of drugs that can be delivered (Prausnitz, 2016). Some of the most common advantages and disadvantages of various transdermal drug delivery systems are listed in Table 1.

Transdermal drug delivery systems have been placed in three generations. The first generation considered the delivery

of drugs that are able to cross the skin with little enhancement or an absence of enhancement. The second generation aimed to deliver small molecules by increasing the permeability of the skin through the use of driving forces. The third generation aimed to deliver macromolecules and vaccines across the stratum corneum layer using thermal ablation, electroporation, cavitation ultrasound, microdermabrasion, and microneedles (Prausnitz and Langer, 2008). In this review, we discuss the important approaches employed in the three generations of transdermal drug delivery. Furthermore, we explore some promising approaches for transdermal delivery. In addition, we consider how microneedles can be manufactured using three-dimensional (3D) printing methods.

FIRST-GENERATION TRANSDERMAL DRUG DELIVERY

Transdermal drug delivery systems were first developed from herbal plants and progressed to the current patch technology. The formulations in this generation, which include ointments, creams, sprays, gels, or patches, must be sufficiently low molecular weight, lipophilic, and effective at low doses. Owing to these factors, there is a limited number of drugs that can be delivered through the skin. For example, lipophilic drugs are capable of crossing the stratum corneum and reaching the capillary bed at a slow rate (Prausnitz and Langer, 2008).

SECOND-GENERATION TRANSDERMAL DRUG DELIVERY

The purpose of the second generation of transdermal drug delivery is to increase skin permeability by temporarily disrupting the function of the stratum corneum to allow drugs to cross it. This generation involves the use of different enhancements that do not damage the dermis. Conventional chemical enhancement, iontophoresis, and noncavitational ultrasound are three approaches associated with this

Table 1. Advantages and Disadvantages Associated with Transdermal Drug Delivery Approaches

Advantages	Disadvantages
Convenience	High cost
Steady infusion	Local irritation
Stable blood levels	Low permeability limits
Self-administration	No rapid drug release
Flexibility of termination	Variation in barrier function
Improved patient compliance	Molecular size restriction

This table was reprinted with permission from Sabbagh and Kim (2022).




Figure 2. Various types and methods of drug delivery to the skin using microneedles (MNs). (a) MNs are applied to the skin and (b) are used for drug delivery. Solid MNs are used as a pretreatment, after which the drug in a topical formulation moves through pores in the skin. After insertion of drug-coated MNs into the skin, the coating dissolves in the aqueous environment of the skin (coated MN). Drug-loaded MNs are made of water-soluble or biodegradable materials that encapsulate the drug; the drug is released in the skin upon MN dissolution (dissolving MN). Hollow MNs are used to inject liquid formulations containing the drug into the skin (hollow MN). This image was reprinted with permission from Kim et al. (2012).

generation (Chu et al., 2016; Prausnitz and Langer, 2008; Williams, 2003). Conventional chemical enhancers modulate epidermal lipid biosynthesis, which enhances drug delivery (Tsai et al., 1996). Amphiphilic molecules or solvents and surfactants disrupt the intracellular lipids of the stratum corneum by disorganizing molecular packing or extracting lipids. Conventional chemical enhancers can be used to deliver small molecules; however, these materials have limitations in terms of delivering hydrophilic macromolecules. The other approaches involve adding a cleavable chemical group (e.g., esters or carbonates) to the drug to enhance the lipophilicity of the drug. One advantage of this approach is that it is not associated with skin irritation (Kiptoo et al., 2006).

Iontophoresis involves the application of a constant low-voltage electric current on the skin that increases the delivery rate of ionized molecules or drugs (Banga et al., 1999); the principle of charge repulsion is the basis of this approach. For example, if there is interest in delivering a positively charged drug, then the positively charged drug needs to be dissolved in the electrolyte with the same polarity (Wang et al., 2005). The use of electrical energy to increase the penetration of an electrically charged compound is known as iontophoresis (Green et al., 1993). The amount of delivered drug can be adjusted by the amount of the current that is applied; this approach may be used for the transdermal delivery of peptides and oligonucleotides (Banga et al., 1999; Green, 1996).

The other member of the second generation of transdermal drug delivery is noncavitational ultrasound. Fellingner and Schmidt (1954) showed that ultrasound was able to facilitate the movement of hydrocortisone ointment across an avascular membrane in 1950. An ultrasound device was approved by the United States Food and Drug Administration in 2004 for local dermal anesthesia with lidocaine (Azagury et al., 2014). Ultrasound pressure waves, which are too high in frequency for the human ear, disrupt the stratum corneum lipid structure and increase the skin permeability for small and lipophilic compounds.

THIRD-GENERATION TRANSDERMAL DRUG DELIVERY

This generation of transdermal drug delivery aims to deliver vaccines, proteins, and macromolecules across the stratum corneum layer. This strategy involves enhancing the rate of drug delivery while protecting the deeper layers of the skin from injury. Technologies associated with this generation include electroporation, microdermabrasion, thermal ablation, cavitational ultrasound, and microneedle-based delivery (Arora et al., 2008; Prausnitz and Langer, 2008).

Electroporation is also considered a third-generation transdermal drug delivery approach (Pliquett et al., 1995; Prausnitz et al., 1993). Electroporation uses high voltage pulses in a short period of time to disrupt the skin lipid bilayer. This disruption process makes pathways for small-molecule drugs, vaccines, peptides, and DNA to be delivered (Denet et al., 2004; Li et al., 2008). Because the stratum corneum has much more electrical resistance than other layers, most of the electric current concentrates in this layer and thus does not affect the deeper layers (Pliquett and Weaver, 2007). After the disruption of the stratum corneum lipid bilayer by the electric current, the electrical resistance of the stratum corneum drops rapidly, which can lead to injury of deeper layers. The closer the probes are, the less risk of injury in the deeper layers (Pliquett and Weaver, 2007). This technology is widely used for animal studies; owing to the complexity of this technology, its use in humans is limited (Prausnitz and Langer, 2008).


Cavitational ultrasound involves the production of cavitation bubbles with exposure to ultrasound energy (Leighton, 2012). The cavitation bubbles can enable targeted effects and enhance transdermal drug delivery (Ogura et al., 2008; Prausnitz and Langer, 2008). Because cavitation bubbles in the dense stratum corneum cannot grow, they collapse and form shock waves. These shock waves facilitate the movement of the drug across the stratum corneum (Paliwal et al., 2006; Prausnitz and Langer, 2008). Park et al. (2012) showed that cavitation bubbles improve skin permeability by increasing cavitation activities over a range of frequencies >1 MHz. In another study, Park et al., (2019, 2014) demonstrated the delivery of FITC-dextran to a depth of 500 μm through sonophoresis with cavitation (Liao et al., 2016).

Thermal ablation generates heat of hundreds of degrees in microseconds to milliseconds; the short heat duration limits the heat from transferring to the tissues below (Bramson et al., 2003; Levin et al., 2005). The high temperature in the stratum corneum vaporizes the aqueous part of the stratum corneum and makes paths for transdermal drug delivery. The temperature generated in the stratum corneum must be higher than the water boiling point for it to be vaporized (Park et al., 2008). Thermal ablation creates a microscale channel through the stratum corneum, which may be used to deliver drugs or vaccines (Arora et al., 2008).

Microdermabrasion involves the degradation of the stratum corneum and other skin layers in an effort to increase skin permeability. Previous studies demonstrate that micrometer-scale abrasion results in higher rates of drug delivery (Prausnitz and Langer, 2008). The microdermabrasion method is able to remove layers of the epidermis beyond the stratum corneum to enhance the drug delivery rate (Andrews et al., 2011). Insulin, lidocaine, and 5-fluorouracil have been

Figure 3. Schematic illustration of the self-powered, on-demand transdermal drug delivery system.

The system includes (a) transdermal patches, a TENG, and a power management circuit; (b) a screen-printed electrode, showing the mechanism of drug release when the TENG is operated to power electrodes A and B; and (c) the radial-arrayed rotary TENG. This image was reprinted with permission from Ouyang et al. (2019). DEX, dexamethasone; PPy, polypyrrole; PTFE, polytetrafluoroethylene; SPE, screen printed electrode; TENG, triboelectric nanogenerator.



delivered by microdermabrasion of the skin (Herndon et al., 2004). A vaccine delivery can also be facilitated by microdermabrasion (Glenn et al., 2007).

Microneedles are micrometer-scale needle-shaped structures that can be used to deliver drugs or vaccines through the skin. Microneedles are painless because they have minimal or no interaction with nerve endings in the papillary dermis (Henry et al., 1998). These devices make paths through the epidermis to facilitate transdermal drug or vaccine delivery. Both biodegradable and nonbiodegradable types of microneedles have been evaluated. Nonbiodegradable microneedles are fabricated from nonbiodegradable materials by conventional subtractive or 3D printing (additive manufacturing) techniques. Solid nonbiodegradable microneedles have been processed out of several types of materials, including silicon (McAllister et al., 2003), various types of epoxies (Ami et al., 2011; Fernández et al., 2009; Park et al., 2007), and polymethylmethacrylate (Moon et al., 2005). Nonbiodegradable microneedles can be created with hollow and solid geometries; biodegradable microneedles have been created with solid geometries. Figure 2 contains a schematic that shows all three types of microneedles. Solid microneedles create pores in the skin; drugs can enter deeper layers of the skin through these microneedle-generated pores. When exposed to the aqueous environment of the human skin, the coating carrying the medication in drug-coated microneedles releases the medication. In drug-coated microneedles, the coating carrying the drug is dissolved when it comes in contact with the aqueous environment of the human skin. In nonbiodegradable hollow microneedles, drugs are delivered through pressure- or diffusion-driven flow. Dissolving microneedles breaks down on exposure to the aqueous environment within the skin, releasing both the biodegradable polymer and the drug within the skin (Kim et al., 2012).

Nonbiodegradable microneedles can be produced in hollow and solid formats. The solid microneedles can be used to make channels in the stratum corneum; a topical solution containing the drug can be applied to the microneedle-perforated skin. Drugs can be used in the form of ointment, cream, gel, or lotion; the drug-containing formulation will penetrate deeper skin layers through the perforations (Kim et al., 2012). Alternately, the drug can be coated on the microneedle; during skin penetration, the microneedle will carry the drug to deeper layers of the skin (Gill and Prausnitz, 2007). Silicon microneedles have been fabricated through a reactive ion etching; these devices were used to increase the permeability of a model drug, calcein, in human skin (Henry et al., 1998). Metallic microneedles are fabricated through 3D laser ablation (Omatsu et al., 2010), laser cutting (Davis et al., 2005), and wet etching (Matriano et al., 2002). In another study, microneedle patches with 57 microneedles were coated with the photodynamic therapy agent using a micro-precision dip coater. The 5-aminolevulinic acid delivered through the microneedles was shown to reach deeper regions of the skin than through topical application in an *in vivo* dermal model (Jain et al., 2016). It should be noted that nonbiodegradable microneedles are associated with the generation of hazardous waste.

Hollow microneedles are useful for drug or vaccine delivery by diffusion- or pressure-driven flow (Lee et al., 2018). There is no device-related upper limit to the amount of drug that can be delivered using hollow microneedles. Moreover, the drugs used with hollow microneedles can be in liquid form; there is no need to solidify drugs that are distributed in liquid form for use with hollow microneedle devices. This type of microneedle is used in the same manner as conventional hypodermic syringes (Ita, 2015). Another use of hollow microneedles is the acquisition of interstitial fluid for bio-sensing by a sensor (Joshi et al., 2022; Miller et al., 2016;




Figure 4. Scanning electron micrographs of unmodified and quantum-dot coated Gantrez microneedles. The micrographs show (a) unmodified Gantrez microneedles and (b) quantum-dot coated Gantrez microneedles, which were produced using visible light dynamic mask microstereolithography-micromolding and piezoelectric inkjet printing. This image was reprinted with permission from Boehm et al. (2011).

Sanjay et al., 2018). Hollow microneedles have the potential to extract a precise volume of interstitial fluid for biosensing applications (Bhatnagar et al., 2017).

Biodegradable microneedles are available in both solid and hollow forms. One technical challenge with biodegradable microneedles involves making devices with sufficient fracture resistance to pierce the stratum corneum without fracture (Narayan, 2014). Polymeric microneedles are usually fabricated using the micromolding technique; water evaporation, UV light curing, and heat curing are often used to create the solid microneedle device from the liquid precursor. Carboxymethyl cellulose, Gantrez AN material (Boehm et al., 2012), fibroin (You et al., 2011), dextrin (Ito et al., 2006), dextran (Fukushima et al., 2011), chitosan (Chen et al., 2012), poly methylvinyl ether (McCrudden et al., 2014), polylactic-co-glycolic acid (He et al., 2020), and poly glycolic-acid (Park et al., 2007) are commonly solidified by drying or water evaporation. Polyethylene glycol diacrylate (Takahashi et al., 2017) and polylactic acid (Park et al., 2005) resins containing a photoinitiator are cured using UV light. Polyvinylpyrrolidone (A Machekposhti et al., 2017) is mixed with thermoinitiator that is solidified by heating at 60 °C for 5 hours. Water evaporation during

microneedle manufacturing may be accelerated by the use of a vacuum pump or centrifugation (Kim et al., 2012). Heat or UV light curing methods are faster but may negatively affect the drug structure. In the fabrication process, drugs are altered through interactions with reactive monomers, photoinitiators, high temperatures, or UV light (Jung and Jin, 2021; van der Maaden et al., 2012). Another approach for loading a drug on a biodegradable microneedle involves the use of a coating process; however, the total volume of drug that can be incorporated within a microneedle through a coating process is limited (Bariya et al., 2012).

EMERGING TRANSDERMAL DRUG DELIVERY TOOLS

Advances in transdermal drug delivery technology have made it possible to deliver a therapeutic amount of a drug across human skin. Several device-based transdermal delivery techniques have been demonstrated (Ramadon et al., 2022). For example, Ouyang et al. (2019) explored the efficiency of a triboelectric nanogenerator (TENG) as a miniaturized transdermal device to activate iontophoresis treatment for an enhancement in drug delivery efficiency. Figure 3 shows the schematic of the drug delivery technology consisting of transdermal patch electrodes, the TENG, and a power management circuit. In another study, Arunprasert et al. (2022) described the use of nanostructured lipid carriers—embedded transdermal patches, which were used for the delivery of capsaicin.

Similarly, the use of microparticles and quantum dot nanostructures is also being explored as tools for transdermal drug delivery. For example, Tadros et al. (2020) described the use of STAR particles (star-shaped metallic particles with micron-scale projections designed to penetrate the skin) as a straightforward transdermal technique for the delivery of a wide range of drugs. They show that the efficiency of the fluorouracil drug delivered through STAR particles is enhanced, preventing the growth of subcutaneous melanoma and prolonging the life of mice. Roy et al. (2020) described the use of a thermoresponsive polymeric composite film made up of carbon quantum dots and cyclodextrin as a nontoxic and fluorescent transdermal drug carrier with improved penetration functionality.

Microneedles have emerged as attractive transdermal drug delivery devices because of their capability for sustained drug release and sensing. For example, Shukla et al., 2023 reported the design of a disposable microneedle device for interstitial fluid extraction as well as the monitoring of lactate, glucose, and potassium ions. A detailed review of the various types of microneedles and microneedle fabrication methods is given in the subsequent sections.


THE 3D PRINTING OF SOLID MICRONEEDLES

Inkjet printing

Inkjet printing is an additive manufacturing technique that has been used in the printing of solid microneedles. This technique reproduces images on a substrate by ejecting the ink as droplets to predetermined positions (Singh et al., 2010). Inkjet printing is widely explored as a key bioprinting technique because of its low cost, high speed, and high throughput. On the basis of the process of generating droplets, inkjet printing can be classified as continuous inkjet

Figure 5. A comparison of the interaction of a single photon by UV light with the interaction of two photons by NIR light.

(a) Comparison of the absorption energy of a single photon by UV light with two photons by NIR light. (b) Comparison of the excitation volume of (i) one-photon excitation with (ii) two-photon excitation. In 2PP, regions outside laser focus are less likely to exceed the polymerization threshold of the photoresist. This phenomenon allows the fabrication of complex 3D structures because the proximity effect in TPA is significantly less than that in OPA (Faraji Rad et al., 2021). 2PP, two-photon polymerization; 3D, three-dimensional; NIR, near-infrared; OPA, one-photon absorption; TPA, two-photon absorption.



printing and drop-on-demand (DOD) printing; the DOD inkjet printing approach is primarily used for biomedical and pharmaceutical applications (Azizi Machekposhti et al., 2020). It has been demonstrated that piezoelectric inkjet printing can be used to load gauze with antibacterial and antifungal pharmacologic agents that are difficult to dissolve in aqueous solutions for treating mixed wounds (Azizi Machekposhti et al., 2021). Boehm et al. (2011) fabricated biodegradable acid copolymer microneedles through visible light dynamic mask microstereolithography-micromolding and subsequent inkjet printing. Figure 4 shows the scanning electron microscope images of the as-grown and quantum dot coated-Gantrez microneedles prepared by the combination of visible light dynamic mask microstereolithography-micromolding and subsequent inkjet printing; this study indicated the versatility of this combination approach for fabricating loaded microneedles. By combining inkjet printing with micromolding, they demonstrated the possibility of fabricating solid microneedles with controlled size and composition. Another study used inkjet printing to apply insulin-containing layers to metal microneedles for transdermal delivery (Ross et al., 2015). Surface analysis of the printed layers revealed homogeneous and uniform layers; no defects were noted. They demonstrated rapid insulin release rates from the printed surface, implying that inkjet printing is an effective approach for the transdermal delivery of insulin

in the solid state. In another study, Uddin et al. (2015) used inkjet printing to coat metal microneedle arrays with anti-neoplastic agents for transdermal delivery. They found that inkjet printing performance depends on the applied voltage, nozzle size, and the duration of the pulse (Uddin et al., 2015).

Two-photon polymerization

Two-photon polymerization is an additive manufacturing technique that has been utilized to fabricate hollow microneedles with a variety of geometries. The absorption energy associated with a single photon of UV light and the absorption energy associated with two photons of near-infrared light are shown in Figure 5. It is a technique that enables the fabrication of 3D structures from computer-aided design models; structures with features below 100 nm can be prepared using this approach (Faraji Rad et al., 2021). It is thus possible to fabricate complex microneedle structures in a straightforward and reliable manner that cannot be achieved by conventional manufacturing methods such as photolithography, etching, and injection molding. Faraji Rad et al. (2021) fabricated microneedles through two-photon polymerization; the arrays were successfully penetrated into rabbit ears without fracture (Faraji Rad et al., 2021). Another study used two-photon polymerization and micromolding to create dissolving microneedle arrays containing complex




Figure 6. The hollow MN array component of a point-of-care system. Optical images of MN arrays on (a) a square plate and (b) a cap. SEM images of (c) an MN array, (d) an MN tip, and (e) an MN (oblique view). Keyence laser scanning optical microscopy 3D images of the (f) MN and (g) dimensions of the MN as indicated by the plot of the height (y-axis) and width of the needle (x-axis). Optical images of trypan blue-coated punctured porcine skin using MN arrays of height of (h) 750 μm , (i) 800 μm , (j) 900 μm , and (k) 950 μm . Trypan blue was applied to the MN array-treated skin for visualization of the MN array-generated pores as shown in Figure 3h–k. The MN arrays were inserted into the skin through manual application. The MN array penetrated the stratum corneum layer of the porcine skin without damage to the MN tips (Shukla et al., 2023). 3D, three-dimensional; MN, microneedle; SEM, scanning electron microscope.

undercut features; the microneedle tips were coated with an adjuvant vaccine component (Faraji Rad et al., 2021). Plamadeala et al. (2020) developed pyramidal microneedle arrays that replicated the features of insect anatomy, which allow for the passive transportation of liquid on the microneedle lateral surface. It should be noted that the slow writing speed and high operational costs limit the large-scale commercial application of two-photon polymerization technique for 3D printing of biomedical devices. Faraji Rad et al. (2021) suggest that it is feasible to mass produce low-cost microneedle patches for application in theranostics and immunization at the point of care. However, improvements to the throughput of two-photon polymerization may be needed to clinically translate this approach in a cost-effective manner.

Digital light processing

Digital light processing is a resin-based 3D printing technique that employs light to cure resin through a projector in a layer-by-layer manner according to a computer model. The use of a projector enables the curing of a full layer each time, allowing for faster print times than other 3D printing techniques (Zhang et al., 2019). Digital light processing is being investigated for production of hollow microneedles because it can produce high-resolution structures more quickly than traditional stereolithography methods (Economidou et al.,

2018). Mathew et al. (2021) showed that microneedle arrays fabricated through digital light processing could sustain a load of up to 300 N. In another study, Yao et al. (2019) reported on the fabrication of biocompatible microneedles through a high-precision digital light processing method. They showed that the stiffness of the microneedles can be controlled by optimizing the printing parameters. Similarly, digital light processing was used for 3D structuring of protein-based microneedles (Shin and Hyun, 2021). This study reported a facile technique to develop a 3D protein structure in an aqueous solution through digital light processing, which was difficult to fabricate through other 3D printing techniques. Sachan et al. (2021) reported on the fabrication of solid microneedle arrays using 3D printing and digital light processing technologies; they demonstrated that the microneedles successfully penetrated human skin. Their study indicates that digital light processing may be a feasible approach for the manufacturing of polytetrafluoroethylene-based microneedles and other medical devices. Figure 6 shows the images of hollow polymer microneedle arrays manufactured through a digital light processing technique for use in a point-of-care system. The microneedles were used for the extraction of interstitial fluid and the detection of glucose, lactate, and potassium ions in ex vivo porcine skin (Shukla et al., 2023).

CONCLUSIONS

This review paper describes the history of transdermal drug delivery and the development of the field. Three generations of transdermal drug delivery were considered. The developments associated with the three generations of transdermal drug delivery as well as applications of relevant technologies were described. Emergent transdermal drug delivery techniques are discussed with a detailed review of the functionality and methods of fabrication of microneedles. As such, the features of each technique were critically evaluated for different types of microneedles. Material properties and printing resolution are the two key factors that play a vital role in the performance of microneedles. In this regard, 3D printing technology is emerging as an important solution to developing clinically useful microneedles. The 3D printing-based prototyping and manufacturing methods enable the versatile production of microneedles with shape complexity and the capability for mass manufacturing. The various techniques described in this review highlight the diverse applications of 3D printing technology in the production and development of microneedles. Owing to the benefits of 3D printing technologies, we anticipate that these techniques will be of significant importance for clinical manufacturing of microneedles and other patient-customized drug delivery systems in the near future.

ORCIDiS

Roger J. Narayan: <http://orcid.org/0000-0002-4876-9869>

Naveen Joshi: <http://orcid.org/0000-0002-1371-3291>

Sina Azizi Macheuposhti: <http://orcid.org/0000-0003-0070-1918>

CONFLICT OF INTEREST

The authors state no conflict of interest.

ACKNOWLEDGMENTS

One of the authors (RJN) acknowledges support from the United States National Science Foundation Awards 1762202 and 2029974. This review paper has no associated datasets and only cites already published human or animal studies.

AUTHOR CONTRIBUTIONS

Writing – Original Draft Preparation: SAM, NJ, RJN

REFERENCES

- A Macheuposhti S, Soltani M, Najafizadeh P, Ebrahim SA, Chen P. Biocompatible polymer microneedle for topical/dermal delivery of tranexamic acid. *J Control Release* 2017;261:87–92.
- Ami Y, Tachikawa H, Takano N, Miki N. Formation of polymer microneedle arrays using soft lithography. *J Micro/Nanolith MEMS MOEMS* 2011;10:011503.
- Andrews S, Lee JW, Choi SO, Prausnitz MR. Transdermal insulin delivery using microdermabrasion. *Pharm Res* 2011;28:2110–8.
- Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. *Int J Pharm* 2008;364:227–36.
- Arunprasert K, Pornpitchanarong C, Piemvuthi C, Siraprapornsakul S, Sripeangchan S, Lertsrimongkol O, et al. Nanostructured lipid carrier-embedded polyacrylic acid transdermal patches for improved transdermal delivery of capsaicin. *Eur J Pharm Sci* 2022;173:106169.
- Azagury A, Khoury L, Enden G, Kost J. Ultrasound mediated transdermal drug delivery. *Adv Drug Deliv Rev* 2014;72:127–43.
- Azizi Macheuposhti S, Movahed S, Narayan RJ. Physicochemical parameters that underlie inkjet printing for medical applications. *Biophys Rev* 2020;1:011301.
- Azizi Macheuposhti S, Zhang B, Sachan R, Vanderwal L, Stafslie SJ, Narayan RJ. Patterned surfaces with the controllable drug doses using inkjet printing. *J Mater Res* 2021;36:3865–76.
- Banga AK, Bose S, Ghosh TK. Iontophoresis and electroporation: comparisons and contrasts. *Int J Pharm* 1999;179:1–19.
- Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. *J Pharm Pharmacol* 2012;64:11–29.
- Bhatnagar S, Dave K, Venuganti VVK. Microneedles in the clinic. *J Control Release* 2017;260:164–82.
- Boehm RD, Miller PR, Hayes SL, Monteiro-Riviere NA, Narayan RJ. Modification of microneedles using inkjet printing. *AIP Adv* 2011;1:22139.
- Boehm RD, Miller PR, Singh R, Shah A, Stafslie S, Daniels J, et al. Indirect rapid prototyping of antibacterial acid anhydride copolymer microneedles. *Biofabrication* 2012;4:011002.
- Bramson J, Dayball K, Eveleigh C, Wan YH, Page D, Smith A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. *Gene Ther* 2003;10:251–60.
- Chen MC, Ling MH, Lai KY, Pramudityo E. Chitosan microneedle patches for sustained transdermal delivery of macromolecules. *Biomacromolecules* 2012;13:4022–31.
- Chien YW. *Transdermal route of peptide and protein drug delivery*. New York, NY: Marcel Dekker; 1991. p. 667–89.
- Chu LY, Ye L, Dong K, Compans RW, Yang C, Prausnitz MR. Enhanced stability of inactivated influenza vaccine encapsulated in dissolving microneedle patches. *Pharm Res* 2016;33:868–78.
- Davis SP, Martanto W, Allen MG, Prausnitz MR. Hollow metal microneedles for insulin delivery to diabetic rats. *IEEE Trans Biomed Eng* 2005;52:909–15.
- Denet AR, Vanbever R, Pr eat V. Skin electroporation for transdermal and topical delivery. *Adv Drug Deliv Rev* 2004;56:659–74.
- Economidou SN, Lamprou DA, Douroumis D. 3D printing applications for transdermal drug delivery. *Int J Pharm* 2018;544:415–24.
- Faraji Rad Z, Prewett PD, Davies GJ. High-resolution two-photon polymerization: the most versatile technique for the fabrication of microneedle arrays. *Microsyst Nanoeng* 2021;7:71.
- Fellinger K, Schmid J. Klinik and therapies des chronischen gelenkreumatismus. *JAMA* 1954;155:322.
- Fern andez LJ, Altuna A, Tijero M, Gabriel G, Villa R, Rodr guez MJ, et al. Study of functional viability of SU-8-based microneedles for neural applications. *J Micromech Microeng* 2009;19:025007.
- Forbes RJ. *Studies in ancient technology*. Leiden, the Netherlands: E. J. Brill; 1964.
- Fukushima K, Ise A, Morita H, Hasegawa R, Ito Y, Sugioka N, et al. Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. *Pharm Res* 2011;28:7–21.
- Gaskell E. Great moments in medicine and pharmacy: a history of medicine and pharmacy in pictures. *Med Hist* 1967;11:320.
- Geller MJ. *Ancient Babylonian medicine: theory and practice*. Chichester, UK: John Wiley & Sons; 2010.
- Gill HS, Prausnitz MR. Coating formulations for microneedles. *Pharm Res* 2007;24:1369–80.
- Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC, et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. *Expert Rev Vaccines* 2007;6:809–19.
- Green PG. Iontophoretic delivery of peptide drugs. *J Control Release* 1996;41:33–48.
- Green PG, Flanagan M, Shroot B, Guy R. Iontophoretic drug delivery. *Drugs Pharm Sci* 1993;59:311–33.
- Guy RH, Hadgraft J, editors. *Transdermal drug delivery*. New York: M. Dekker; 2003. viii.
- He M, Yang G, Zhao X, Zhang S, Gao Y. Intradermal implantable PLGA microneedles for etonogestrel sustained release. *J Pharm Sci* 2020;109:1958–66.
- Henry S, McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery [published correction appears in *J Pharm Sci* 1998;88:948] *J Pharm Sci* 1998;87:922–5.
- Henshilwood CS, d'Errico F, Van Niekerk KL, Coquinot Y, Jacobs Z, Lauritzen SE, et al. A 100,000-year-old ochre-processing workshop at Blombos Cave, South Africa. *Science* 2011;334:219–22.

- Herndon TO, Gonzalez S, Gowrishankar TR, Anderson RR, Weaver JC. Transdermal microconduits by microscission for drug delivery and sample acquisition. *BMC Med* 2004;2:12.
- Ita K. Transdermal delivery of drugs with microneedles-potential and challenges. *Pharmaceutics* 2015;7:90–105.
- Ito Y, Hagiwara E, Saeki A, Sugioka N, Takada K. Feasibility of microneedles for percutaneous absorption of insulin. *Eur J Pharm Sci* 2006;29:82–8.
- Jain AK, Lee CH, Gill HS. 5-aminolevulinic acid coated microneedles for photodynamic therapy of skin tumors. *J Control Release* 2016;239:72–81.
- Joshi P, Riley PR, Mishra R, Azizi Macheuposhti S, Narayan R. Transdermal polymeric microneedle sensing platform for fentanyl detection in biofluid. *Biosensors* 2022;12:198.
- Jung JH, Jin SG. Microneedle for transdermal drug delivery: current trends and fabrication. *J Pharm Investig* 2021;51:503–17.
- Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. *Adv Drug Deliv Rev* 2012;64:1547–68.
- Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-beta-naltrexol via a codrug linked to hydroxypropion. *J Control Release* 2006;113:137–45.
- Kramer SN. *The Sumerians: Their history, culture, and character*. Chicago, IL: University of Chicago Press; 1963.
- Lee H, Song C, Baik S, Kim D, Hyeon T, Kim DH. Device-assisted transdermal drug delivery. *Adv Drug Deliv Rev* 2018;127:35–45.
- Leighton T. *The acoustic bubble*. Cambridge, MA: Academic press; 2012.
- Levin G, Gershonowitz A, Sacks H, Stern M, Sherman A, Rudaev S, et al. Transdermal delivery of human growth hormone through RF-microchannels. *Pharm Res* 2005;22:550–5.
- Li S, Chang L, Teissie J. *Electroporation protocols*. Berlin, Germany: Springer; 2008.
- Liao AH, Ma WC, Wang CH, Yeh MK. Penetration depth, concentration and efficiency of transdermal α -arbutin delivery after ultrasound treatment with albumin-shelled microbubbles in mice. *Drug Deliv* 2016;23:2173–82.
- Magner LN, Kim OJ. *A history of medicine*. Boca Raton, FL: CRC Press; 2017.
- Mathew E, Pitzanti G, Gomes dos Santos AL, Lamprou DA. Optimization of printing parameters for digital light processing 3D printing of hollow microneedle arrays. *Pharmaceutics* 2021;13:1837.
- Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, Nyam K, et al. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. *Pharm Res* 2002;19:63–70.
- McAllister DV, Wang PM, Davis SP, Park JH, Canatella PJ, Allen MG, et al. Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies. *Proc Natl Acad Sci USA* 2003;100:13755–60.
- McCrudden MT, Alkilani AZ, McCrudden CM, McAlister E, McCarthy HO, Woolfson AD, et al. Design and physicochemical characterisation of novel dissolving polymeric microneedle arrays for transdermal delivery of high dose, low molecular weight drugs. *J Control Release* 2014;180:71–80.
- Miller PR, Narayan RJ, Polsky R. Microneedle-based sensors for medical diagnosis. *J Mater Chem B* 2016;4:1379–83.
- Moghimi HR, Shafizade A, Kamlinejad M. *Drug delivery systems in Iranian traditional pharmacy*. Tehran, Iran: Traditional Medicine and Materia Medica Research Center, SBMU; 2011.
- Moon SJ, Lee SS, Lee HS, Kwon TH. Fabrication of microneedle array using LIGA and hot embossing process. *Microsyst Technol* 2005;11:311–8.
- Narayan RJ. Transdermal delivery of insulin via microneedles. *J Biomed Nanotechnol* 2014;10:2244–60.
- Ogura M, Paliwal S, Mitragotri S. Low-frequency sonophoresis: current status and future prospects. *Adv Drug Deliv Rev* 2008;60:1218–23.
- Omatsu T, Chujo K, Miyamoto K, Okida M, Nakamura K, Aoki N, et al. Metal microneedle fabrication using twisted light with spin. *Opt Express* 2010;18:17967–73.
- Ouyang Q, Feng X, Kuang S, Panwar N, Song P, Yang C, et al. Self-powered, on-demand transdermal drug delivery system driven by triboelectric nanogenerator. *Nano Energy* 2019;62:610–9.
- Packard FR. Four thousand years of pharmacy, an outline history of pharmacy and the allied sciences. *Ann Med Hist* 1927;9:418–9.
- Paliwal S, Menon GK, Mitragotri S. Low-frequency sonophoresis: ultrastructural basis for stratum corneum permeability assessed using quantum dots. *J Invest Dermatol* 2006;126:1095–101.
- Park D, Park H, Seo J, Lee S. Sonophoresis in transdermal drug delivery. *Ultrasonics* 2014;54:56–65.
- Park D, Ryu H, Kim HS, Kim YS, Choi KS, Park H, et al. Sonophoresis using ultrasound contrast agents for transdermal drug delivery: an in vivo experimental study. *Ultrasound Med Biol* 2012;38:642–50.
- Park D, Won J, Shin UC, Park H, Song G, Jang J, et al. Transdermal drug delivery using a specialized cavitation seed for ultrasound. *IEEE Trans Ultrason Ferroelectr Freq Control* 2019;66:1057–64.
- Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. *J Control Release* 2005;104:51–66.
- Park JH, Lee JW, Kim YC, Prausnitz MR. The effect of heat on skin permeability. *Int J Pharm* 2008;359:94–103.
- Park JH, Yoon YK, Choi SO, Prausnitz MR, Allen MG. Tapered conical polymer microneedles fabricated using an integrated lens technique for transdermal drug delivery. *IEEE Trans Biomed Eng* 2007;54:903–13.
- Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. *Br J Pharmacol* 2015;172:2179–209.
- Plamadeala C, Gosain SR, Hischen F, Buchroithner B, Puthukodan S, Jacak J, et al. Bio-inspired microneedle design for efficient drug/vaccine coating. *Biomed Microdevices* 2020;22:8.
- Pliquett U, Langer R, Weaver JC. Changes in the passive electrical properties of human stratum corneum due to electroporation. *Biochim Biophys Acta* 1995;1239:111–21.
- Pliquett U, Weaver JC. Feasibility of an electrode-reservoir device for transdermal drug delivery by noninvasive skin electroporation. *IEEE Trans Biomed Eng* 2007;54:536–8.
- Prausnitz M. Inactivated influenza vaccine delivered by microneedle patch or by hypodermic needle. 2016.
- Prausnitz MR, Bose VG, Langer R, Weaver JC. Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. *Proc Natl Acad Sci USA* 1993;90:10504–8.
- Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol* 2008;26:1261–8.
- Ramadan D, McCrudden MTC, Courtenay AJ, Donnelly RF. Enhancement strategies for transdermal drug delivery systems: current trends and applications. *Drug Deliv Transl Res* 2022;12:758–91.
- Ross S, Scoutaris N, Lamprou D, Mallinson D, Douroumis D. Inkjet printing of insulin microneedles for transdermal delivery. *Drug Deliv Transl Res* 2015;5:451–61.
- Roy A, Samanta S, Singha K, Maity P, Kumari N, Ghosh A, et al. Development of a thermoresponsive polymeric composite film using cross-linked β -cyclodextrin embedded with carbon quantum dots as a transdermal drug carrier. *ACS Appl Bio Mater* 2020;3:3285–93.
- Sabbagh F, Kim BS. Recent advances in polymeric transdermal drug delivery systems. *J Control Release* 2022;341:132–46.
- Sachan R, Nguyen AK, Lu J, Erdmann D, Zhang JY, Narayan RJ. Digital light processing-based 3D printing of polytetrafluoroethylene solid microneedle arrays. *MRS Commun* 2021;11:896–901.
- Sanjay ST, Zhou W, Dou M, Tavakoli H, Ma L, Xu F, et al. Recent advances of controlled drug delivery using microfluidic platforms. *Adv Drug Deliv Rev* 2018;128:3–28.
- Shin D, Hyun J. Silk fibroin microneedles fabricated by digital light processing 3D printing. *J Ind Eng Chem* 2021;95:126–33.
- Shukla S, Macheuposhti SA, Joshi N, Joshi P, Narayan RJ. Microneedle-integrated device for transdermal sampling and analyses of targeted biomarkers. *Small Sci* 2023;3. <https://doi.org/10.1002/smsc.202200087>.
- Singh M, Haverinen HM, Dhagat P, Jabbour GE. Inkjet printing-process and its applications. *Adv Mater* 2010;22:673–85.
- Tadros AR, Romanyuk A, Miller IC, Santiago A, Noel RK, O'Farrell L, et al. STAR particles for enhanced topical drug and vaccine delivery. *Nat Med* 2020;26:341–7.
- Takahashi H, Heo YJ, Shimoyama I. Scalable fabrication of PEGDA microneedles using UV exposure via a rotating prism. *J Microelectromech Syst* 2017;26:990–2.

- Tsai JC, Guy RH, Thornfeldt CR, Gao WN, Feingold KR, Elias PM. Metabolic approaches to enhance transdermal drug delivery. 1. Effect of lipid synthesis inhibitors. *J Pharm Sci* 1996;85:643–8.
- Uddin MJ, Scoutaris N, Klepetsanis P, Chowdhry B, Prausnitz MR, Douroumis D. Inkjet printing of transdermal microneedles for the delivery of anticancer agents. *Int J Pharm* 2015;494:593–602.
- van der Maaden K, Jiskoot W, Bouwstra J. Microneedle technologies for (trans)dermal drug and vaccine delivery. *J Control Release* 2012;161:645–55.
- Wang Y, Thakur R, Fan Q, Michniak B. Transdermal iontophoresis: combination strategies to improve transdermal iontophoretic drug delivery. *Eur J Pharm Biopharm* 2005;60:179–91.
- Wester RC, Maibach HI. Percutaneous absorption. In: *Topical drug bioavailability, bioequivalence, and penetration*. Berlin, Germany: Springer; 1993. p. 3–15.
- Williams A. *Transdermal and topical drug delivery: from theory to clinical practice*. London, United Kingdom: Pharmaceutical press; 2003.
- Yao W, Li D, Zhao Y, Zhan Z, Jin G, Liang H, et al. 3D printed multi-functional hydrogel microneedles based on high-precision digital light processing. *Micromachines (Basel)* 2019;11:17.
- You X, Chang J-h, Ju B-K, Pak JJ. Rapidly dissolving fibroin microneedles for transdermal drug delivery. *Mater Sci Eng C* 2011;31:1632–6.
- Zhang J, Hu Q, Wang S, Tao J, Gou M. Digital light processing based three-dimensional printing for medical applications. *Int J Bioprint* 2019;6:242.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>